GMDN FOCUS



Welcome to your Summer 2023 edition of GMDN Focus.

GUDID DATABASE UPDATED TO INCLUDE GMDN CODE

The Global Medical Device Nomenclature (GMDN) Code has been added to the AccessGUDID Database of medical device identification information. The addition of GMDN codes to the database creates enhanced search and retrieval capabilities for all AccessGUDID users, including patients, care givers, health care providers, hospitals, and industry.

The Global Unique Device Identification Database (GUDID) is a database administered by the Food and Drug Administration (FDA) that serves as a reference catalogue for medical devices and technology. AccessGUDID is an online portal created by the FDA which gives access to medical device data held within GUIDID.

You can read more **here**.



READ MORE

GMDN LAUNCHES NEW WEBSITE

Our new site will support the GMDN Agency’s focus to consolidate GMDN as the leading nomenclature across the world as well as maximising stakeholder engagement to further increase GMDN adoption.

This website launch is part of our strategic review of 2023 and is the first phase of investment in our digital transformation project. The GMDN database and members website will be upgraded and refreshed later in the year as we continue to meet the evolving needs of all of our stakeholders.

Visit our new site **here**.

READ MORE

HOW CAN THE GMDN SUPPORT POST-MARKET MEDICAL DEVICE SURVEILLANCE AND VIGILANCE

Our CEO, Deniz Bruce, has written a blog explaining how the GMDN can support post-market medical device surveillance and vigilance. To help Regulators, Manufacturers, and healthcare professionals in ensuring the safety and efficacy of medical devices.

You can read the full blog **here**.

"As the CEO of the Global Medical Device Nomenclature (GMDN) Agency, I am continuously amazed by the benefits that a standardised medical device nomenclature can provide to the healthcare industry.

One area where the GMDN can be particularly useful is in post-market surveillance and vigilance.

Post-market surveillance and vigilance are critical components of ensuring the safety and efficacy of medical devices. Healthcare professionals and Regulators alike rely on this process to identify and address any issues that may arise after a device has been approved and put on the market. "

- DENIZ BRUCE, CEO OF THE GMDN AGENCY

READ MORE

GMDN AGENCY COLLEAGUES DELIVER TRAINING TO MALAYSIAN MDA IN PARTNERSHIP WITH APACMED

Colleagues from the GMDN Agency in partnership with The Asia Pacific Medical Technology Association (APACMed) have delivered training to the Malaysian Medical Device Authority (MDA).

Training provided for the MDA included the structure of the GMDN, Regulatory use, Manufacturers views for Regulators and use cases of the GMDN.

GMDN UPDATE

In June and July, there were 307 new or amended Terms added to the GMDN.

Find out why Terms need amending and how we update the GMDN.

Log in to view saved Terms:
gmdnagency.org/Account/Login

STAY CONNECTED WITH GMDN

Login/Register
My account

News from GMDN
Get in touch

Want to share your experience of using GMDN or have an idea on how we can work together? Please get in touch.

Email **communications@gmdnagency.org**